Aurobindo Pharma secured USFDA approvals for two drugs
The approvals are for two separate drugs used for treatment of enlarged prostate and bacterial infections in infants.
New Delhi, May 4, 2013: Aurobindo Pharma has bagged two final approvals from the US health regulator to sell the generic versions of two separate drugs used for treatment of enlarged prostate and bacterial infections in infants.
The company has announced that the US Food & Drug Administration (USFDA) has granted it approval to manufacture and market Tamsulosin Hydrochloride Capsules of strength 0.4mg.
It may be noted here that the market size of the product is estimated at US$ 244 million for the twelve month ending September 2012, according to IMS.
The second approval received by the company is for Clindamycin Palmitate Hydrochloride for oral solution of strength 75mg (base)/5ml.
The market size of the product is estimated at US$ 57 million for the 12 months ending September 2012 according to IMS.